Navigation Links
CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
Date:1/11/2010

ove patients' overall survival by 33% over what can be attained with standard treatment alone (without the addition of Multikine therapy) at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for this Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients having squamous cell carcinoma (cancer) of the head and neck.

About Multikine

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received surgery, chemotherapy and/or radiation therapy, which can limit their effectiveness.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also devel
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
4. CEL-SCI Expands H1N1 Flu Virus Work
5. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
6. CEL-SCI Posts New Corporate Presentation to Website
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... , March 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... received a patent acceptance notice from the Israeli patent ... to prevent or reduce tissue damage caused by an ... when cardiac vessels are opened after a blockage causing ... stroke victims. Damage can be caused to ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... NEW YORK, Feb. 15, 2011 Reportlinker.com ... is available in its catalogue: ... CE countries 2011 - Comparative analysis, reimbursement ... http://www.reportlinker.com/p0395681/Generic-and-innovative-drug-market-in-CE-countries-2011---Comparative-analysis-reimbursement-policies-and-development-forecasts-for-2011-2013 ...
... 15, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... a conference call and a live Internet webcast along with ... a.m. ET (7:00 a.m. PT) to discuss results for the ... number to participate on this call is (877) 295-5743, confirmation ...
Cached Medicine Technology:Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013 2Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 The American College ... be on the topics of the DAOM Program as well ... Program Overview Webinar will be hosted by Dr. Carla Wilson, ... the next steps on how to prepare for the spring ... March 25, March 27, April 1 and April 3. Attendees ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Baruch ... new team of nationally renowned scientists to focus exclusively ... a move that nearly triples its research capacity and ... solely on hepatitis B and liver cancer in the ... Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu Su ...
(Date:3/26/2015)... 26, 2015 Visiting Nurse Association ... 18th annual gala fundraiser, Lighting the Way, Brightening the ... at The Madison Hotel in Morristown, NJ. , ... by renowned musician Rio Clemente, delightful cuisine, an extensive ... Dave Hertzel. Additionally, two prestigious awards will be presented ...
(Date:3/26/2015)... NY (PRWEB) March 26, 2015 ... its 30th “Introduction to Hyperbaric Medicine” course, which ... Medical Society (UHMS) and the National Board of ... provides the 40-hour course 4 times a year ... around the NY tri-state region; registration is available ...
(Date:3/26/2015)... March 26, 2015 On March 5, ... Matthews is out for the season with a torn ... while the Trail Blazers were competing against Dallas, and ... specialist, Izzy Silva, M.D., who has treated many ... and whether it could be prevented. , "Part ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... the U.S. Department of Agriculture found that a compound in ... compound, pterostilbene, is a potent antioxidant that could be developed ... effects than some commercial drugs that are currently used to ... cause of cancer death in the United States. ...
... discovered by researchers at Weill Cornell Medical College could prove ... ,The compound, called SS31, is able to cross the ... to stroke-related tissue damage. ,"In our experiments, we ... stroke led to a much smaller area of brain tissue ...
... specially developed proteins could make our bodies more resistant ... ,Steaks and chicken fillets laced with some ... against oxidation – oxidation is considered a major cause ... Shchepinov, a former Oxford University scientist, has found ...
... University of Wisconsin-Madison claim that they can efficiently seek ... cells//. This is very similar to the Nature's way ... ,The new tumor targeting strategy, presented today (March ... Chemical Society, cleverly harnesses one of the body's natural ...
... wisdom, in order to deal with teenage pregnancies and ... ,Improving pupil-teacher relationships and raising a teenager’s self-confidence ... will do the trick, say the researchers. In this ... newer ones such as focusing on sexual risks ,and ...
... the omega-3 fatty acids docosahexaenoic acid (DHA) successfully reduced ... trial, backing up previous results with higher doses. // ... which is likely to be of clinical significance with ... subjects," wrote lead author Hannah Theobald from King's College ...
Cached Medicine News:Health News:Eat Berries, Prevent Colon Cancer 2Health News:Eat Berries, Prevent Colon Cancer 3Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:'School Sermons' Need a Comeback 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: